ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients

Screening Criteria: * Females ≥18 years of age * Patient must sign an Informed Consent Form * Patient is suspected to have one of the following * advanced stage Epithelial Ovarian Cancer (EOC) * advanced stage Primary Peritoneal Carcinomatosis * advanced stage Fallopian Tube Carcinoma Inclusion Criteria: * Females ≥18 years of age * Diagnosis by pathology of one of either advanced stage EOC, Primary Peritoneal Carcinomatosis, or Fallopian Tube Carcinoma * Newly diagnosed * Recurrent * Patient provided an evaluable tumor or peritoneal fluid specimen prior to initiating chemotherapy for ChemoINTEL assay analysis * Patient received at least 3 cycles of standard of care chemotherapy for advanced stage EOC with single agent or combination of drugs summarised as below, following biopsy OR surgical resection * Carboplatin * Cisplatin * Cyclophosphamide-4HC active metabolite * Docetaxel * Doxorubicin * Etoposide * Fluorouracil * Gemcitabine * Ifosfamide-4HI active metabolite * Irinotecan * Oxaliplatin * Paclitaxel * Pemetrexed * Topotecan * Vinorelbine * Bevacizumab (Avastin) * Patients will have an appropriate evaluation after their third cycle and sixth cycle of SOC chemotherapy to document response by either RECIST 2009 v1.1, CA-125 KELIM Scoring, and/or circulating tumor DNA longitudinal monitoring * Patient signed Informed Consent Form Exclusion Criteria: * Patient has not signed an ICF to participate in a clinical investigation * Patient has a cancer other than advanced stage EOC * Patient did NOT receive SOC chemotherapy, single agents or combination treatment from the indicated list above. * Patients did NOT have sufficient viable cells recovered from either a fresh tumor dissociation or peritoneal fluid specimen collected prior to initiating chemotherapy available for the minimum ChemoINTEL assay analysis of Carboplatin, Cisplatin, Docetaxel, and Paclitaxel test conditions